Want to see IN:BIOFILCHEM full AI Analyst Report?
BIOFILCHEM Stock Chart & Stats
₹33.59
-₹0.32(-0.55%)
At close: 4:00 PM EST
₹33.59
-₹0.32(-0.55%)
Day’s Range― - ―
52-Week Range₹25.60 - ₹47.50
Previous CloseN/A
Volume25.08K
Average Volume (3M)6.87K
Market Cap
₹545.34M
Enterprise Value₹578.40M
Total Cash (Recent Filing)₹33.26M
Total Debt (Recent Filing)₹30.20M
Price to Earnings (P/E)19.7
Beta1.64
Next Earnings
Aug 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.71
Shares Outstanding16,273,800
10 Day Avg. Volume7,559
30 Day Avg. Volume6,869
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.95
Price to Sales (P/S)1.48
P/FCF Ratio-51.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative LeverageSustained low leverage through 2021–2025, and a still-modest 14.0% D/E in 2026, provides lasting financial flexibility. Lower debt reduces solvency risk, cushions the firm against operational volatility, and preserves capacity to raise capital or fund restructuring over the next several months.
Equity Base Has GrownAn expanding equity base strengthens the balance sheet and enhances long-term resilience. Higher equity improves creditor confidence, increases borrowing headroom, and gives management scope to absorb cyclical losses or invest in product or process improvements without immediate reliance on external short-term financing.
Positive Reported Net Margin (2026)A reported 9.8% net margin in 2026 shows the company can produce bottom-line profit despite weak operating margins. Persisting net profitability can enable dividend capacity, tax stability, or retained earnings to rebuild working capital, provided earnings drivers are made more consistent over time.
Bears Say
Weak Cash GenerationRepeated negative operating and free cash flows across multiple years signal poor cash conversion and working-capital strain. This undermines the company's ability to self-fund capex, repay debt, and sustain operations, increasing reliance on external financing and raising execution risk over the medium term.
Sharp 2026 Revenue DropA one-third revenue decline in 2026 materially reduces scale economies and revenue visibility. Such volatility impairs planning, weakens bargaining power with suppliers/customers, and can make fixed-cost absorption harder, pressuring margins and cash generation for the coming quarters.
Margin CompressionSteep declines in gross and EBITDA margins indicate rising cost pressure or pricing erosion that cut into core profitability. Persistently compressed margins reduce the firm's buffer against demand shocks, limit reinvestment capacity, and make recovery dependent on structural fixes to costs or product mix.
Biofil Chemicals & Pharmaceuticals Ltd. News
BIOFILCHEM FAQ
What was Biofil Chemicals & Pharmaceuticals Ltd.’s price range in the past 12 months?
Biofil Chemicals & Pharmaceuticals Ltd. lowest stock price was ₹25.60 and its highest was ₹47.50 in the past 12 months.
What is Biofil Chemicals & Pharmaceuticals Ltd.’s market cap?
Biofil Chemicals & Pharmaceuticals Ltd.’s market cap is ₹545.34M.
When is Biofil Chemicals & Pharmaceuticals Ltd.’s upcoming earnings report date?
Biofil Chemicals & Pharmaceuticals Ltd.’s upcoming earnings report date is Aug 18, 2026 which is in 31 days.
How were Biofil Chemicals & Pharmaceuticals Ltd.’s earnings last quarter?
Biofil Chemicals & Pharmaceuticals Ltd. released its earnings results on May 30, 2026. The company reported ₹0.13 earnings per share for the quarter, beating the consensus estimate of N/A by ₹0.13.
Is Biofil Chemicals & Pharmaceuticals Ltd. overvalued?
According to Wall Street analysts Biofil Chemicals & Pharmaceuticals Ltd.’s price is currently Overvalued.
Does Biofil Chemicals & Pharmaceuticals Ltd. pay dividends?
Biofil Chemicals & Pharmaceuticals Ltd. does not currently pay dividends.
What is Biofil Chemicals & Pharmaceuticals Ltd.’s EPS estimate?
Biofil Chemicals & Pharmaceuticals Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biofil Chemicals & Pharmaceuticals Ltd. have?
Biofil Chemicals & Pharmaceuticals Ltd. has 16,273,800 shares outstanding.
What happened to Biofil Chemicals & Pharmaceuticals Ltd.’s price movement after its last earnings report?
Biofil Chemicals & Pharmaceuticals Ltd. reported an EPS of ₹0.13 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -3.921%.
Which hedge fund is a major shareholder of Biofil Chemicals & Pharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in IN:BIOFILCHEM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Biofil Chemicals & Pharmaceuticals Ltd.
Biofil Chemicals and Pharmaceuticals Limited, headquartered in Indore, India, is primarily involved in the country's pharmaceutical and chemical industries. This company supplies a comprehensive array of fundamental drugs and chemical compounds, including sodium chloride, potassium chloride, sodium citrate, diethyl carbamazine citrate, ferrous sulphate, dried ferrous sulphate, ferrous fumerate, micro crystalline cellulose, and dicyclomine hydrochloride. Additionally, its product line features plastic dippers and caps. Beyond its product offerings, Biofil also provides contract manufacturing services for pharmaceutical items. The company was founded in 1985.
Technical Analysis
Bal Pharma Limited
―
―
Lasa Supergenerics Ltd.
―
Mangalam Drugs & Organics Ltd.
―
Vaishali Pharma Ltd.
―